● Recruiting

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies

Condition: Non-Hodgkin Lymphoma (NHL) · Acute Lymphoblastic Leukemia (ALL), Adult · Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

PhaseEARLY_Phase 1

Planned participants19

Who can joinAll sexes, 18 Years to 70 Years

Healthy volunteersNo

About this study

Evaluate the safety, pharmacokinetic (PK) characteristics, and pharmacodynamic (PD) characteristics of LV009 injection in subjects with relapsed/refractory CD19-positive hematologic malignancies.

This description comes directly from the study's public registry record.

Talk to the study team

Xingbing Wang, Doctor · +86-13856007984 · wangxingbing@ustc.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

PersonGen.Anke Cellular Therapeutice Co., Ltd.

Hefei, Anhui, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07312630